Pemirolast sodium

Drug Profile

Pemirolast sodium

Alternative Names: CRD 007

Latest Information Update: 28 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardoz
  • Developer Cardoz; Karolinska Institute; Karolinska University Hospital; RSPR Pharma; Sahlgrenska University Hospital; University of Amsterdam
  • Class Antiallergics; Antiasthmatics; Nonsteroidal anti-inflammatories; Pyridines; Pyrimidinones; Small molecules
  • Mechanism of Action Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic asthma; Asthma
  • No development reported Vasculitis

Most Recent Events

  • 28 Apr 2017 Chemical structure information added
  • 24 Feb 2017 RSPR Pharma completes a phase-II trial in Asthma (Adjunctive treatment) in Bulgaria, Denmark, Poland, United Kingdom (NCT02615080)
  • 01 Nov 2016 Phase-II clinical trials in Allergic asthma in Sweden (PO) (NCT03119714)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top